The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell …
X Zhang, J Chen, MZ Han, H Huang, E Jiang… - Journal of hematology & …, 2021 - Springer
The consensus recommendations in 2018 from The Chinese Society of Hematology (CSH)
on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem …
on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem …
How I treat acquired aplastic anemia
A Bacigalupo - Blood, The Journal of the American Society of …, 2017 - ashpublications.org
Acquired severe aplastic anemia (SAA) is a rare hematologic disease associated with
significant morbidity and mortality. Immune destruction of hemopoietic stem cells plays an …
significant morbidity and mortality. Immune destruction of hemopoietic stem cells plays an …
Guidelines for the use of platelet transfusions
L Estcourt, J Birchall, S Allard, S Bassey… - British journal of …, 2016 - ora.ox.ac.uk
The demand for platelets in England was stable at around 220,000 adult therapeutic doses
(ATD) per year until 2007/8 at which point demand has increased year on year to 275,000 …
(ATD) per year until 2007/8 at which point demand has increased year on year to 275,000 …
Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia
Severe aplastic anemia (SAA) is a marrow failure disorder with high morbidity and mortality.
It is treated with bone marrow transplantation (BMT) for those with fully matched donors, or …
It is treated with bone marrow transplantation (BMT) for those with fully matched donors, or …
Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide
Severe aplastic anemia (SAA) is a stem cell disorder often treated with bone marrow
transplantation (BMT) to reconstitute hematopoiesis. Outcomes of related HLA …
transplantation (BMT) to reconstitute hematopoiesis. Outcomes of related HLA …
[PDF][PDF] Guidelines on the use of irradiated blood components
T Foukaneli, P Kerr, PHB Bolton-Maggs… - Br J …, 2020 - medi-guide.meditool.cn
Purpose To provide healthcare professionals with clear guidance on situations when the
use of irradiated blood components is indicated. The term 'blood component'means the …
use of irradiated blood components is indicated. The term 'blood component'means the …
Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant
LP Xu, S Jin, SQ Wang, LH Xia, H Bai, SJ Gao… - Journal of hematology & …, 2017 - Springer
Background Haploidentical donor (HID) hematopoietic stem cell transplantation (HSCT) is
an alternative treatment method for severe aplastic anemia (SAA) patients lacking suitable …
an alternative treatment method for severe aplastic anemia (SAA) patients lacking suitable …
[PDF][PDF] 单倍型供者造血干细胞移植治疗重型再生障碍性贫血的单中心研究
杜志丛， 赵艳丽， 曹星玉， 刘德琰， 熊敏… - 临床血液学 …, 2023 - lcxyen.whuhzzs.com
目的: 探讨单倍型造血干细胞移植(haplo-HSCT) 治疗重型再生障碍性贫血(SAA) 的疗效. 方法:
回顾性分析2012 年9 月—2019 年11 月接受HID-HSCT 的120 例儿童和成人SAA …
回顾性分析2012 年9 月—2019 年11 月接受HID-HSCT 的120 例儿童和成人SAA …
Review of current transfusion therapy and blood banking practices
Transfusion Medicine is a dynamically evolving field. Recent high-quality research has
reshaped the paradigms guiding blood transfusion. As increasing evidence supports the …
reshaped the paradigms guiding blood transfusion. As increasing evidence supports the …
Approach to the diagnosis of aplastic anemia
AE DeZern, JE Churpek - Blood Advances, 2021 - ashpublications.org
Establishing a diagnosis of aplastic anemia (AA) can be challenging, but it is absolutely
critical to appropriate management, especially differentiating between acquired and …
critical to appropriate management, especially differentiating between acquired and …